CN105030791B - Application of the 25(OH)VD in Intracranial Benign Tumor brain tumor is treated - Google Patents
Application of the 25(OH)VD in Intracranial Benign Tumor brain tumor is treated Download PDFInfo
- Publication number
- CN105030791B CN105030791B CN201510360731.1A CN201510360731A CN105030791B CN 105030791 B CN105030791 B CN 105030791B CN 201510360731 A CN201510360731 A CN 201510360731A CN 105030791 B CN105030791 B CN 105030791B
- Authority
- CN
- China
- Prior art keywords
- tumor
- application
- hypophysoma
- treated
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to a kind of application of 25(OH)VD in Intracranial Benign Tumor brain tumor is treated, pass through application of the 25(OH)VD in Intracranial Benign Tumor brain tumor is treated, serum 25(OH)VD is lifted to 25 ng/l by 10 ng/l, checks MRI, hypophysoma volume-diminished.
Description
Technical field
The present invention provides a kind of application of medicine, more particularly to a kind of 25(OH)VD swells in treatment Intracranial Benign Tumor brain
Application in knurl, especially suitable for the application in meningioma and hypophysoma.
Background technology
Meningioma and hypophysoma are the common benign tumours of neurosurgery.It is generally divided into invasion and Non-Invasive.Due to
The characteristic of invasive growth, invasive meningioma and hypophysoma be in the treatment of neurosurgery benign tumour one most intractable ask
Topic.Any reason causes the invasion and attack of these tumours and fast-growth not to will be apparent that also at present.
25(OH)VD is vitamin, and a kind of hormone.It suppresses cell growth, promotes differentiation, anti-sense
Dye, anti-inflammatory and immunoregulation effect.But 25(OH)VD is in Intracranial Benign Tumor tumour especially meningioma and hypophysoma
Effect is not but fully aware of.
The content of the invention
The present invention is directed to above-mentioned problems of the prior art, there is provided a kind of 25(OH)VD is good in treatment encephalic
Application in property brain tumor.
The daily oral vitamin D 800-1200IU of Intracranial Benign Tumor patient with brain tumors, take altogether 25-60 days.
Have particular application as, the daily oral vitamin D 1000IU of Intracranial Benign Tumor patient with brain tumors, take altogether 30 days.
Described Intracranial Benign Tumor brain tumor is meningioma and hypophysoma.
Advantages of the present invention effect is as follows：
By application of the 25(OH)VD in Intracranial Benign Tumor brain tumor is treated, serum 25(OH)VD is by 10
Ng/l liftings check MRI, hypophysoma volume-diminished to 25 ng/l.
Brief description of the drawings
Figure 1A is normal person and the content schematic diagram of 25(OH)VD in Patients with Meningiomas serum.
Figure 1B is the average content schematic diagram of 25(OH)VD in Patients with Meningiomas serum.
Fig. 1 C are the content of 25(OH)VD and the average schematic diagram of meningioma volume in serum.
Fig. 1 D are the content of 25(OH)VD and the negatively correlated schematic diagram of meningioma volume in serum.
Fig. 2A is normal person and the content schematic diagram of 25(OH)VD in hypophysoma patients serum.
Fig. 2 B are the average content schematic diagram of 25(OH)VD in hypophysoma patients serum.
Fig. 2 C are the content of 25(OH)VD and the average schematic diagram of hypophysoma volume in serum.
Fig. 2 D are the content of 25(OH)VD and the negatively correlated schematic diagram of hypophysoma volume in serum.
Fig. 3 A are treatment forebrain gross tumor volume schematic diagram.
Fig. 3 B are treatment hindbrain gross tumor volume schematic diagram.
Embodiment
By detecting the serum specimen of meningioma 16 and 30 patients of hypophysoma, the patient of meningioma and hypophysoma is found
Serum in 25(OH)VD content be all in deficiency state.Average 7.91 ng/mL of meningioma, hypophysoma average 13.25
Ng/mL, such as Figure 1A, 1B, shown in Fig. 2A, 2B.And the content of the vitamin D in serum and the volume of tumour and size are in negative
Correlation, such as Fig. 1 C, 1D；Shown in Fig. 2 C, 2D.These results suggest that vitamin D deficiency be cause meningioma and hypophysoma attack and
The main cause that tumour increases.Meningioma and the daily oral vitamin D 1000IU of hypophysoma patient, take altogether 30 days.
Serum 25(OH)VD is lifted to 25 ng/l by 10 ng/l.Check MRI, hypophysoma volume-diminished, as shown in Figure 3.
In summary, for the carcinoid patient of encephalic, including meningioma and hypophysoma, on the one hand can pass through
Detection serum in vitamin D content come judge tumour invasion and growth speed, on the other hand we can also pass through
Correct the shortage of 25(OH)VD in serum and suppress the invasion and attack of meningioma and hypophysoma and growth with deficiency, reach treatment
The purpose of these tumours.
Embodiment
The present invention is by following examples, and further the citing description present invention, does not limit the invention in any way
On the premise of without departing substantially from technical scheme, those of ordinary skill in the art made for the present invention easily realize any
Change or change are both fallen within the interest field of the present invention.
Embodiment 1
The daily oral vitamin D 1000IU of Patients with Meningiomas, take altogether 30 days.
Embodiment 2
The daily oral vitamin D 1000IU of hypophysoma patient, take altogether 30 days.
Embodiment 3
The daily oral vitamin D 800IU of Patients with Meningiomas, take altogether 60 days.
Embodiment 4
The daily oral vitamin D 1200IU of hypophysoma patient, take altogether 25 days.
Claims (1)
1. 25(OH)VD is preparing the application in treating Intracranial Benign Tumor brain tumor medicine；
The daily oral vitamin D 1000IU of Intracranial Benign Tumor patient with brain tumors, take altogether 30 days；
Described Intracranial Benign Tumor brain tumor is meningioma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510360731.1A CN105030791B (en) | 2015-06-26 | 2015-06-26 | Application of the 25(OH)VD in Intracranial Benign Tumor brain tumor is treated |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510360731.1A CN105030791B (en) | 2015-06-26 | 2015-06-26 | Application of the 25(OH)VD in Intracranial Benign Tumor brain tumor is treated |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105030791A CN105030791A (en) | 2015-11-11 |
| CN105030791B true CN105030791B (en) | 2017-12-22 |
Family
ID=54438159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510360731.1A Expired - Fee Related CN105030791B (en) | 2015-06-26 | 2015-06-26 | Application of the 25(OH)VD in Intracranial Benign Tumor brain tumor is treated |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105030791B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1301298A (en) * | 1998-03-25 | 2001-06-27 | 卡坦诺根公司 | Methods for prevention and treatment of cancer |
| US6566351B1 (en) * | 1995-12-28 | 2003-05-20 | Chugai Seiyaku Kabushiki Kaisha | Malignant tumor metastasis inhibitors |
-
2015
- 2015-06-26 CN CN201510360731.1A patent/CN105030791B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566351B1 (en) * | 1995-12-28 | 2003-05-20 | Chugai Seiyaku Kabushiki Kaisha | Malignant tumor metastasis inhibitors |
| CN1301298A (en) * | 1998-03-25 | 2001-06-27 | 卡坦诺根公司 | Methods for prevention and treatment of cancer |
Non-Patent Citations (1)
| Title |
|---|
| Anti-Tumor Effects of 1,25-Dihydroxyvitamin D3 and Vitamin D Analogs;Gert-Jan C.M. van den Bemd等;《Current Pharmaceutical Design》;20001231;第6卷(第7期);第717页第1段-718页第2段，表1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105030791A (en) | 2015-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peyrade et al. | Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation | |
| WO2014205555A8 (en) | Methods and uses for diagnosis and treatment of prostate cancer | |
| WO2015049688A3 (en) | Patient-specific immunotherapy for treating heterogeneous tumors | |
| CN105030791B (en) | Application of the 25(OH)VD in Intracranial Benign Tumor brain tumor is treated | |
| Mao et al. | Iron oxide nanoparticles for biomedical applications: An updated patent review (2015–2021) | |
| Killion et al. | Nivolumab induced psoriasis successfully treated with acitretin | |
| Droitcourt et al. | Docetaxel‐induced photo‐recall phenomenon | |
| Sun et al. | Effect of ginsenoside-Rg3 on the expression of VEGF and TNF-α in retina with diabetic rats | |
| CN104490993A (en) | Method for preparing cyclocarya paliurus extract with antioxidant activity and application with cyclocarya paliurus extract as aldose reductase inhibitor | |
| Chen et al. | Squamous cell carcinoma occurring in the pelvis after total hysterectomy and bilateral salpingo-oophorectomy for an ovarian mature teratoma with malignant transformation | |
| CN205340938U (en) | Stem of noble dendrobium cooling device | |
| Verma | Maxillary Sinus Cancer–Early Diagnosis Helps | |
| Kim et al. | Clinical Characteristics of Metastatic Choroidal Tumors in Korean Patients. | |
| Griebling | Re: The Challenges of bacillus of Calmette-Guerin (BCG) Therapy for High Risk Non Muscle Invasive Bladder Cancer Treatment in Older Patients | |
| Kuehn | Different routes of application in mistletoe therapy–Effect on bone marrow and blood profile. Clinical significance | |
| CN206730024U (en) | A kind of scrotal support | |
| MUTALIK et al. | UNIQUE CLINICAL PRESENTATIONS OF DEEP FUNGAL INFECTIONS INVOLVING THE ORAL CAVITY: A REPORT OF TWO CASES AND REVIEW OF THE LITERATURE | |
| Huddart et al. | Changes in BMI after treatment of testicular cancer are due to age and hormonal function and not chemotherapy | |
| Wang et al. | C20 ADVANCES IN THE CELLULAR AND MOLECULAR UNDERSTANDING OF LUNG CANCER: The Examination Of Cd47 And Its Potential Therapy Target Study On The Migration And Invasion In Non-Small Cell Lung Cancer | |
| Griffiths | G-CSF cost-neutral for early-stage breast cancer | |
| Saini et al. | Neurological dysfunction and mobile phones | |
| Cacicedo et al. | Efficacy of radiotherapy for painful bone metastases in elderly patients | |
| Tabatabaeefar et al. | Radiosurgery for meningioma: Evaluation of radiological outcome and contributing factors of recurrence | |
| CN204601372U (en) | A kind of novel tumor is to oxygen therapy cover | |
| Labidi et al. | Quality of life in breast cancer Tunisian women: A monocentric survey |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181130 Address after: No. 36, San Hao street, peace zone, Shenyang, Liaoning, Liaoning Patentee after: Shengjing Hospital of China Medical University Address before: 11 004 Shengjing Hospital Affiliated to China Medical University, 36 Sanhao Street, Heping District, Shenyang City, Liaoning Province Patentee before: Zhang Lei |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171222 Termination date: 20200626 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |